A-B-CMV is NOT Easy as 1-2-3 in Pediatrics: Pediatric Considerations for Cytomegalovirus (CMV) Management in Hematopoietic Stem Cell Transplant Patients

**Activity Title:**

Erin Tamulonis

**Speaker:**

**Objectives:**

1. Identify pathophysiology and diagnostics for cytomegalovirus (CMV) infection in hematopoietic stem cell transplant (HCT) patients.
2. Discuss recommendations for CMV prophylaxis, with a focus on differences between pediatric and adult HCT patients.
3. Describe treatment options for CMV in HCT, including refractory or resistant cases.

**Presentation Abstract:**

Cytomegalovirus (CMV) is a common virus that rarely causes illness in healthy patients but can cause clinically significant infection in patients with weakened immune systems. Hematopoietic stem cell transplant (HCT) recipients with CMV reactivation are at increased risk for morbidity and mortality. Recent guidelines published in 2021 address prophylaxis and treatment of CMV in both pediatric and adult patients. Historically, there was no guideline supported prophylactic agent specific for CMV until the FDA approval of letermovir in 2017. In the 2021 guidelines, maribavir is discussed as an investigational agent, though it was FDA approved in late 2021 for post-transplant refractory CMV infection or disease. Current FDA approvals and lack of large pharmacokinetic studies in pediatric patients limit the broad use of letermovir and maribavir in this population; however, case reports demonstrate that these are potential therapeutic options.

**Format:**

[ ]  Live

[ ]  Home study

[ ]  Live and Home study

[x]  Webinar (Live)

January 25, 2023

**Date of Live Activity:**

**Activity length (hr. or CEU): 1 hour**

Topic Designators – activities are related to:

If a CPE activity’s target audience is exclusively for pharmacists, the designation “P” will be used as follows:

[x]  01-P Disease State Management/Drug therapy

[ ]  02-P AIDS therapy

[ ]  03-P Law (related to pharmacy practice)

[ ]  04-P General Pharmacy

[ ]  05-P Patient Safety

[ ]  06-P Immunizations

[ ]  07-P Compounding

[ ]  08-P Pain Management/Opioids

**Audience Questions:**

1. Which of the following is a risk of CMV infection in HCT patients?​
2. Retinitis​
3. End organ damage​
4. Rejection of the graft​
5. All of the above​
6. What is the recommended agent for CMV prophylaxis in CMV seropositive allogeneic HCT recipients, based on the 2021 American Society for Transplantation and Cellular Therapy (ASTCT) guidelines?​
7. Valganciclovir ​
8. Maribavir​
9. Letermovir​
10. Foscarnet​
11. Which of the following is true regarding maribavir?​
12. It is contraindicated in patients < 8 years old​
13. It is FDA approved in pediatric patients ≥ 12 years of age weighing ≥ 35 kg and adults​
14. It is associated with bone marrow suppression​
15. It is an antiretroviral agent ​

**References:**

1. Hakki M, Aitken SL, Danziger-Isakov L, Michaels MG, Carpenter PA, Chemaly RF, Papanicolaou GA, Boeckh M, Marty FM. American Society for Transplantation and Cellular Therapy Series: #3-Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation. *Transplant Cell Ther*. 2021 Sep;27(9):707-719.
2. Yong MK, Shigle TL, Kim YJ, Carpenter PA, Chemaly RF, Papanicolaou GA. American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation*. Transplant Cell Ther.* 2021 Dec;27(12):957-967.
3. Centers for Disease Control and Prevention. About Cytomegalovirus (CMV). 2020. https://www.cdc.gov/cmv/overview.html. Accessed 11 Dec 2022.
4. Green ML, Leisenring W, Xie H, Mast TC, Cui Y, Sandmaier BM, Sorror ML, Goyal S, Özkök S, Yi J, Sahoo F, Kimball LE, Jerome KR, Marks MA, Boeckh M. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. *Lancet Haematol*. 2016 Mar;3(3):e119-27.
5. Chemaly RF, Chou S, Einsele H, Griffiths P, Avery R, Razonable RR, Mullane KM, Kotton C, Lundgren J, Komatsu TE, Lischka P, Josephson F, Douglas CM, Umeh O, Miller V, Ljungman P; Resistant Definitions Working Group of the Cytomegalovirus Drug Development Forum. Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. *Clin Infect Dis*. 2019 Apr 8;68(8):1420-1426.
6. Razonable RR, Inoue N, Pinninti SG, Boppana SB, Lazzarotto T, Gabrielli L, Simonazzi G, Pellett PE, Schmid DS. Clinical Diagnostic Testing for Human Cytomegalovirus Infections. *J Infect Dis*. 2020 Mar 5;221(Suppl 1):S74-S85.
7. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ; Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and MarrowTransplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. *Biol Blood Marrow Transplant*. 2009 Oct;15(10):1143-238.
8. Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, Hubacek P, Navarro D, Cordonnier C, Ward KN; 2017 European Conference on Infections in Leukaemia group. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). *Lancet Infect Dis.* 2019 Aug;19(8):e260-e272.
9. Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S, Ullmann AJ, Katayama Y, Brown J, Mullane KM, Boeckh M, Blumberg EA, Einsele H, Snydman DR, Kanda Y, DiNubile MJ, Teal VL, Wan H, Murata Y, Kartsonis NA, Leavitt RY, Badshah C. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. *N Engl J Med.* 2017 Dec 21;377(25):2433-2444.
10. Marty FM, Ljungman PT, Chemaly RF, Wan H, Teal VL, Butterton JR, Yeh WW, Leavitt RY, Badshah CS. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. *Am J Transplant*. 2020 Jun;20(6):1703-1711.
11. El Chaer F, Shah DP, Chemaly RF. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. *Blood.* 2016 Dec 8;128(23):2624-2636.
12. Shaikh S, Jasiak-Panek N, Park JM. A national survey of valganciclovir dosing strategies in pediatric organ transplant recipients. *Clin Transplant*. 2018 Sep;32(9):e13369.
13. Pappo A, Peled O, Berkovitch M, Bilavsky E, Rom E, Amir J, Krause I, Yarden-Bilavsky H, Scheuerman O, Ashkenazi-Hoffnung L. Efficacy and Safety of a Weight-based Dosing Regimen of Valganciclovir for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients. *Transplantation.* 2019 Aug;103(8):1730-1735.
14. Styczynski J, Tridello G, Xhaard A, et al. Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study*. Bone Marrow Transplant*. 2021;56:1171–1179.
15. Chiereghin A, Belotti T, Borgatti EC, et al. Off-label use of letermovir as preemptive anti-cytomegalovirus therapy in a pediatric allogeneic peripheral blood stem cell transplant. *Infect Drug Resist.* 2021;14:1185–1190.
16. Kilgore JT, Becken B, Varga MG, et al. Use of letermovir for salvage therapy for resistant cytomegalovirus in a pediatric hematopoietic stem cell transplant recipient. *J Pediatric Infect Dis Soc*. 2020;9:486–489~~.~~
17. Strenger V, Sperl D, Kubesch K, et al. Letermovir in paediatric HSCT recipients*. J Antimicrob Chemother.* 2019;74:2820–2821.
18. Kuhn A, Puttkammer J, Madigan T, Dinnes L, Khan S, Ferdjallah A, Kohorst M. Letermovir as CMV Prophylaxis in a Pediatric Cohort: A Retrospective Analysis, Transplantation and Cellular Therapy (2022).
19. Avery RK, Alain S, Alexander BD, et al; SOLSTICE Trial Investigators. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. *Clin Infect Dis*. 2022;75(4):690-701.
20. Maertens J, Cordonnier C, Jaksch P, et al. Maribavir for preemptive treatment of cytomegalovirus reactivation. *N Engl J Med*. 2019;381(12):1136-1147.
21. Papanicolaou GA, Silveira FP, Langston AA, et al. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study. *Clin Infect Dis*. 2019;68(8):1255-1264.
22. Halpern-Cohen V, Blumberg EA. New Perspectives on Antimicrobial Agents: Maribavir*. Antimicrob Agents Chemother.* 2022 Sep 20;66(9):e0240521.